UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-31 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.05 | -0.05 |
| Q1 2022 | 2022-05-05 | -0.07 | -0.07 |
| Q4 2021 | 2022-02-22 | -0.05 | -0.05 |
| Q3 2021 | 2021-11-02 | -0.07 | -0.07 |
| Q2 2021 | 2021-08-03 | -0.09 | -0.09 |
| Q1 2021 | 2021-05-04 | -0.10 | -0.10 |
| Q4 2020 | 2021-02-25 | -0.09 | -0.09 |
| Q3 2020 | 2020-10-29 | -0.08 | -0.08 |
| Q2 2020 | 2020-08-04 | -0.09 | -0.09 |
| 2016-07-11 | Reiterated Rating | FBR & Co | Buy | |
| 2016-07-07 | Reiterated Rating | Cantor Fitzgerald | Not Available to Buy | $9.00 |
| 2016-06-22 | Reiterated Rating | Robert W. Baird | Outperform | $9.00 |
| 2016-06-20 | Reiterated Rating | BTIG Research | Buy | $10.00 |
| 2016-05-23 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-05-23 | Reiterated Rating | FBR & Co | Buy | |
| 2016-05-04 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-04-22 | Reiterated Rating | BTIG Research | Buy | $8.00 to $10.00 |
| 2016-03-16 | Reiterated Rating | FBR & Co. | Outperform | $10.00 |
| 2016-03-16 | Reiterated Rating | Robert W. Baird | Outperform | $9.00 |
| 2016-03-14 | Reiterated Rating | BTIG Research | Buy | |
| 2016-03-10 | Reiterated Rating | Cantor Fitzgerald | Buy | $8.00 |
| 2016-02-11 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2016-02-06 | Reiterated Rating | Stephens | Buy | |
| 2016-02-02 | Reiterated Rating | FBR & Co. | Outperform | $10.00 |
| 2016-01-29 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-01-28 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2016-01-27 | Reiterated Rating | Cantor Fitzgerald | Buy | $8.00 |
| 2016-01-17 | Reiterated Rating | FBR & Co. | Buy | |
| 2015-12-29 | Reiterated Rating | BTIG Research | Buy | |
| 2015-12-23 | Reiterated Rating | BTIG Research | Buy | |
| 2015-12-17 | Downgrade | Wedbush | Outperform to Neutral | $6.50 |
| 2015-12-09 | Reiterated Rating | BTIG Research | Buy | |
| 2015-11-07 | Reiterated Rating | BTIG Research | Buy | |
| 2015-11-01 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-10-07 | Reiterated Rating | Cantor Fitzgerald | Buy | $7.00 |
| 2015-09-30 | Reiterated Rating | Cantor Fitzgerald | Buy | $7.00 |
| 2015-09-16 | Reiterated Rating | Cantor Fitzgerald | Buy | $7.00 |
| 2015-09-15 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-08-19 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-08-10 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-08-10 | Reiterated Rating | Cantor Fitzgerald | Buy | $7.00 |
| 2015-06-30 | Reiterated Rating | MLV & Co. | Buy | $10.00 |
| 2015-05-06 | Reiterated Rating | BTIG Research | Buy | $8.00 |
| 2015-05-06 | Reiterated Rating | Cantor Fitzgerald | Buy | $7.00 |
| 2015-05-06 | Set Price Target | MLV & Co. | Buy | $10.00 |
| 2015-04-24 | Initiated Coverage | BTIG Research | Positive to Buy | $8.00 |
| 2015-02-27 | Reiterated Rating | Cantor Fitzgerald | Buy | $8.00 to $7.00 |
| 2015-02-27 | Reiterated Rating | MLV & Co. | Buy | $7.00 |
| 2015-02-27 | Lower Price Target | Wedbush | Outperform | $7.50 to $6.50 |
| 2015-02-20 | Set Price Target | Wedbush | Buy | $7.50 |
| 2015-02-06 | Reiterated Rating | MLV & Co. | Buy | $8.00 |
| 2014-12-23 | Set Price Target | MLV & Co. | Buy | $10.00 |
| 2014-12-19 | Set Price Target | Cantor Fitzgerald | Buy | $6.00 to $8.00 |
| 2014-12-18 | Reiterated Rating | Wedbush | Buy | $6.50 |
| 2014-12-02 | Boost Price Target | MLV & Co. | Buy | $6.00 to $7.00 |
| 2014-11-10 | Initiated Coverage | Cantor Fitzgerald | Buy | |
| 2014-05-05 | Lower Price Target | Cantor Fitzgerald | Buy | $8.00 to $7.00 |
| 2014-05-02 | Lower Price Target | MLV & Co. | Buy | $8.50 to $6.00 |
| 2013-10-30 | Boost Price Target | Cantor Fitzgerald | Buy | $7.00 to $8.00 |
| 2013-10-21 | Boost Price Target | Cowen and Company | $7.00 to $9.00 | |
| 2013-09-30 | Boost Price Target | Wedbush | Outperform | $6.00 to $7.50 |
| 2013-03-15 | Reiterated | MLV & Co | Buy | $7.50 to $8.50 |
| 2012-04-17 | Initiated | Cantor Fitzgerald | Buy | $5.50 |
| 2012-02-29 | Upgrade | Robert W. Baird | Neutral to Outperform | $3 to $6 |
| 2011-11-10 | Reiterated | MLV & Co | Buy | $4 to $5 |
| 2011-06-03 | Initiated | Wedbush | Outperform | $4 |
| 2011-03-04 | Downgrade | Robert W. Baird | Outperform to Neutral | $4 to $3 |
| 2010-03-09 | Upgrade | Robert W. Baird | Neutral to Outperform | $3 to $5 |
| 2009-08-26 | Upgrade | Avondale | Mkt Perform to Mkt Outperform | $2 to $5 |
| 2009-07-28 | Downgrade | Robert W. Baird | Outperform to Neutral | $3 |
| 2009-05-04 | Downgrade | JMP Securities | Mkt Perform to Mkt Underperform | |
| 2009-02-27 | Downgrade | Avondale | Mkt Outperform to Mkt Perform | |
| 2008-05-02 | Downgrade | JMP Securities | Mkt Outperform to Mkt Perform | |
| 2008-01-29 | Initiated | JMP Securities | Mkt Outperform | |
| 2007-12-05 | Initiated | Susquehanna Financial | Neutral | |
| 2007-05-02 | Downgrade | JMP Securities | Mkt Outperform to Mkt Perform | |
| 2007-02-23 | Reiterated | JMP Securities | Mkt Outperform | $17 to $9 |
| 2016-07-11 | Reiterated Rating | FBR & Co | Buy | |
| 2016-07-07 | Reiterated Rating | Cantor Fitzgerald | Not Available to Buy | $9.00 |
| 2016-06-22 | Reiterated Rating | Robert W. Baird | Outperform | $9.00 |
| 2016-06-20 | Reiterated Rating | BTIG Research | Buy | $10.00 |
| 2016-05-23 | Reiterated Rating | FBR & Co. | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CERS 142 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BAKER BROS. ADVISORS LP | 16.07M |
| BlackRock Inc. | 12.22M |
| Vanguard Group, Inc | 10.45M |
| PRIMECAP MANAGEMENT CO/CA/ | 9.27M |
| Sumitomo Mitsui Trust Holdings, Inc. | 7.33M |
| Nikko Asset Management Americas, Inc. | 7.33M |
| Elk Creek Partners, LLC | 6.24M |
| WASATCH ADVISORS INC | 5.32M |
| STATE STREET CORP | 4.88M |
| BlackRock Fund Advisors | 4.71M |
| RIMA SENVEST MANAGEMENT, L.L.C. | 4.43M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.15M |
| D. E. Shaw & Co., Inc. | 2.87M |
| BlackRock Institutional Trust Company, N.A. | 2.64M |
| KENNEDY CAPITAL MANAGEMENT, INC. | 2.21M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| CORASH LAURENCE M Chief Medical Officer | 2.16% (1602591) | CERS / |
| Greenman William Mariner Sr. VP Bus. Dev. & Marketing | 0.48% (354779) | CERS / |
| GLASSELL CLAES Executive Officer and Director | 0.26% (189457) | CBM / CERS / |
| ANDERSON TIMOTHY B | 0.14% (105573) | CERS / |
| Green Kevin Dennis Chief Accounting Officer | 0.08% (60825) | CERS / |
| ERVIN HOWARD G Vice President, Legal Affairs | 0.06% (42846) | CERS / |
| Moore Carol SR. V.P. Regulatory, Clinical | 0.06% (40841) | CERS / |
| Jayaraman Vivek K Chief Commercial Officer | 0.05% (36034) | CERS / |
| Menard Chrystal Chief Legal Officer | 0.03% (25628) | CERS / |
| COZADD BRUCE C | 0.03% (18921) | CERS / JAZZ / THLD / |
| Swisher Daniel N JR | 0.02% (12336) | CERS / CORT / JAZZ / SNSS / |
| Witney Frank | 0.01% (10133) | AFFX / CERS / PKI / |
| SCHULZE GAIL | 0.01% (10133) | CERS / |
| Benjamin Richard J Chief Medical Officer | 0.01% (8652) | CERS / |
UM